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Abstract
Background Numerous studies have examined prognostic
factors for survival of breast cancer patients, but relatively
few have dealt speciﬁcally with 10+-year survivors.
Methods A review of the PubMed database from 1995 to
2006 was undertaken with the following inclusion criteria:
median/mean follow-up time at least 10 years; overall
survival and/or disease-speciﬁc survival known; and rela-
tive risk and statistical probability values reported. In
addition, we used data from the long-standing Eindhoven
Cancer Registry to illustrate survival probability as indi-
cated by various prognostic factors.
Results 10-year breast cancer survivors showed 90% 5-
year relative survival. Tumor size, nodal status and grade
remained the most important prognostic factors for long-
term survival, although their role decreased over time.
Most studies agreed on the long-term prognostic values of
MI (mitotic index), LVI (lymphovascular invasion), Her2-
positivity, gene proﬁling and comorbidity for either all or a
subgroup of breast cancer patients (node-positive or neg-
ative). The roles of age, socioeconomic status, histological
type, BRCA and p53 mutation were mixed, often
decreasing after correction for stronger prognosticators,
thus limiting their clinical value. Local and regional
recurrence, metastases and second cancer may substantially
impair long-term survival. Healthy lifestyle was consis-
tently related to lower overall mortality.
Conclusions Effects of traditional prognostic factors
persist in the long term and more recent factors need fur-
ther follow-up. The prognosis for breast cancer patients
who have survived at least 10 years is favourable and in-
creases over time. Improved long-term survival can be
achieved by earlier detection, more effective modern
therapy and healthier lifestyle.
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Introduction
Breast cancer (BC) is the most common cancer among
women, with a lifetime risk of up to 12% and a risk of
death of up to 5% [1]. Its incidence has been increasing but
after a period of continuous rise in many industrialized
countries BC mortality has been stable or has even de-
creased in the last 10–15 years [2, 3]. The introduction of
mass mammographic screening programmes also resulted
in earlier detection and diagnosis of small and less
aggressive tumours. This, in combination with therapeutic
improvements, has led to a substantial increase in BC
survivors over the last few decades (Fig. 1). A long-term
survivor is commonly deﬁned as a person who is still alive
5 years after cancer diagnosis [4]. For BC, the relative
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DOI 10.1007/s10549-007-9556-1survival at 5 and 10 years after diagnosis is 88% and 77%,
respectively, both substantially higher than the 5-year rel-
ative survival of all cancers together (64%) [4]. Thus, it
seems logical to consider factors known to play an
important role in predicting 5-year survival of BC patients
and to question their importance in survival 10 years after
diagnosis and even longer. Furthermore, in recent years
major advances in the prognostic value of several molec-
ular markers have been achieved, hence the need to
incorporate this data into our current knowledge. There-
fore, we have summarized available knowledge on the
determinants of survival 10 years or more after breast
cancer diagnosis. We supported our analyses and consid-
erations with data from the population-based, long-stand-
ing Eindhoven cancer registry in the Netherlands.
Methods
We initially searched PubMed, using the search MESH
term for ‘breast neoplasms’ AND ‘prognoses’ AND ‘long-
term’. Only papers published in English between 1995 and
2006 (September) which researched female adults
(19+ years) were included. We retrieved 528 articles and
studied the abstracts (sometimes also the methods section).
We selected only articles that assess or show the results for
those surviving 10 years or longer with cohorts having a
mean/median follow-up of 10 years or longer. If mean/
median follow-up time was not reported, we examined the
proportion of patients who survived 10 years after diag-
nosis, and this ought to be larger than 50%. If, for a speciﬁc
topic of interest, no relevant studies with a follow-up of at
least 10 years were found (such as BRCA mutation or gene
proﬁling, which have been studied only during the last
decade), then studies with the longest available follow-up
were chosen. Furthermore, the following inclusion criteria
were used: overall and/or BC-speciﬁc survival was
reported; relative risk or hazard rate and statistical proba-
bility values were given; at least 250 BC patients included
at the beginning of study. We also searched the reference
lists collected by this search strategy and selected those that
were relevant to both our study question and inclusion
criteria. Reviews and books that gave general overviews
were also included in the reference list.
We present data from the Eindhoven Cancer Registry
(ECR) to illustrate the role of factors such as age, tumour
size, lymph node involvement and time since diagnosis.
Within the Netherlands, ECR is unique because it has
collected follow-up data since 1970, including clinical as-
pects of cancer patients. This is a population-based cancer
registry covering a population of almost 2.4 million people
in 2004 [5]. Cumulative survival proportion was calculated
using the Kaplan Meier method. Relative survival was
calculated by comparing the survival of BC patients to the
general population.
Throughout the text the term long-term and/or survival
will frequently be mentioned; this corresponds to at least
10-year survival unless otherwise indicated.
Results and discussions
Determinants of survival BC 10 years or longer
Patient characteristics
Age at diagnosis Very young women, i.e. younger than
30/35 years [6, 7], exhibited a particularly poor survival as
do those older than 70 (Fig. 2)[ 8, 9]. Young BC patients
were more likely to have a more negative clinical presen-
tation, such as affected lymph nodes, negative for oestro-
gen receptors, and have large tumour with a high fraction
of p53 nuclei and overexpression of c-erb-2 oncoprotein [6,
10, 11]. However, current adjuvant treatment seems to
diminish the poor prognostic value of young age [6]; young
women who did not receive adjuvant treatment had a sig-
niﬁcantly increased risk of dying; those diagnosed at
35–39 years and <35 years had a 1.4 and 2.2 higher risk of
death, respectively, compared to those of 45–49 years [6].
Older patients exhibited higher mortality rates [12], prob-
ably because of less extensive treatment (either related to
advanced age itself or the presence of serious concomitant
diseases (comorbidity)) [13].
Comorbidity Concurrent health conditions (comorbidity)
at the time of BC diagnosis have a signiﬁcant impact on
early [13] as well as long-term survival of BC patients [12].
The most prevalent conditions were cardiovascular disease
(7%), previous cancer (7%) and diabetes mellitus (6%), all
Fig. 1 Proportion of breast cancer patients (3-year moving average)
diagnosed between 1973 and 1993 who survived 10 years or longer in
Southeastern Netherlands
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123becoming more common with increasing age [13]. Com-
pared to those without comorbidity whose 5-year relative
survival was 87%, those with diabetes mellitus or cardio-
vascular disease represented 78% and 83% of the respec-
tive survival estimates [13]. Patients with severe
comorbidity exhibited a 2.7–3.4 higher risk of death in
10 years compared to those without comorbidity [12, 14].
Period of diagnosis Access to care and treatment of BC
has improved over time in most industrialized countries,
which is reﬂected in the higher long-term survival of BC
cases across all age groups and the tumour characteristics
of those diagnosed more recently [15–18]. In Finland,
relative survival 10 years after diagnosis among patients
younger than 50 years increased from 49% for those
diagnosed in 1953–1959 to 68% for the 1983–1989 cohort
[15]. Furthermore, 60% of node-positive BC patients
diagnosed in 1978–1979 in Italy survived 10 years or
longer compared to the 50% probability 10-year survival
for those diagnosed in 1968–1969 [17]. In addition, chan-
ges in BC diagnosis, e.g. screening[19, 20] and better
staging [17], may partly be responsible for the observed
increase in the proportion of survivors.
Time after diagnosis The longer a woman survives BC
the more the prognosis improves, illustrated by conditional
survival [16, 21]. Probably the subgroup of patients who
survived longer had less aggressive tumours due to a dif-
ferent genetic make-up or better life-style. In Australia,
79% of women with localized BC survived 10 years after
diagnosis, yet among those still alive 5 years after diag-
nosis 84% had a 10-year survival [16]. The respective
values for regional vs. advanced BC were 53% and 68%
[16]. Unlike other cancers, relative conditional survival
remained stable below 100% after 12 years of survival and
decreased again after about 19 years (Fig. 3)[ 5]. This may
be a consequence of late recurrences and metastases,
second cancers or late side-effects of treatment [23].
Socioeconomic status (SES) and race A population-based
study of BC patients diagnosed in 1968–1999 in France
showed a diminishing role of SES on excess mortality
among women with BC over these periods [24]. Long-term
follow-up studies reported that women with BC from low
social classes had a 20–50% poorer survival compared to
patients from higher social classes [25, 26], although others
contradicted this [27]. Low SES patients were more likely
to be diagnosed at a later stage, had more aggressive tu-
mour characteristics and might have received sub-optimal
treatment. However, differences in these prognostic factors
did not fully explain the variation in survival according to
social class [25]. This is also the case when breast cancer
survival is studied according to race/ethnicity. Ten years
after treatment 58% of African Americans were still alive
compared to 66% of the white Americans. After adjusting
for other prognostic factors, 41% excess mortality from all
causes was still observed among African Americans com-
pared to caucasians [28]. This suggests other residual fac-
tors such as lifestyle (higher body weight was observed
among African Americans), comorbidity [14], genetics or
variation in the delivery of treatment, which inﬂuence
outcome beyond variation in tumour aggressiveness [29].
Fig. 2 Relative survival of breast cancer patients (n: 13,279)
diagnosed in 1990–2002 and followed until 2004, according to age
at diagnosis in southeastern Netherlands
Fig. 3 Conditional 5-year relative survival (calculated using period
analysis [22] of breast cancer patients diagnosed in southern
Netherlands in 1985–2002 and followed until 2004, according to
age. (Dashed line): diagnosed at 25–49 years, (solid line): diagnosed
at 50–74 years
Breast Cancer Res Treat (2008) 107:309–330 311
123Tumour-related characteristics
Tumour size Tumour size is one of the strongest prog-
nostic indicators (Fig. 4)[ 7, 30], even after 20 years of
follow-up [8, 31]. A larger tumour has been related to more
positive lymph nodes [32], thus their interaction further
inﬂuences the survival from BC. Nonetheless, the inde-
pendence of survival by node status is shown by the lower
10-year overall survival rate found for node-negative pa-
tients with a tumour of 2–5 cm compared to those with a
tumour smaller than 1 cm, 66% vs. 79%, respectively [33].
Histological type The prognostic value of histological
type can be grouped into four: excellent, good, poor and
very poor prognosis [34]. BC with an excellent prognosis,
such as invasive cribriform, tubular [35], tubulo-lobular
and mucinous [36, 37] showed >80% survival at 10 years
[9]. Tubular mixed, mixed ductal with special type, atyp-
ical medullary [38] and alveolar lobular carcinoma have a
good prognosis with a 60–80% 10-year survival. Those
with invasive papillary, classic lobular and medullary
cancers have a worse prognosis. Finally, 10-year survival
among those with ductal, solid lobular, mixed ductal and
lobular carcinoma is below 50% [34]. In most populations
inﬁltrating ductal carcinoma covers about 70% of all
diagnoses [36, 39]. Inﬂammatory BC has a particularly
poor prognosis: about 30% survived 10 years [40].
Histological grade The most widely used grading sys-
tems are Scarff-Bloom-Richardson classiﬁcation, Fisher
grading nuclear system and Nottingham Combined Histo-
logic Grade (NCHG) [41]. The validity of grading has been
subjected to inter-observer reproducibility and subjectivity
[42]. However, higher grades have been quite consistently
associated with lower long-term survival [7, 8, 31, 43–45].
Depending on other prognostic factors, such as nodal status
or tumour size [46, 47], cumulative survival among pa-
tients with the lowest score was 90–94% 10 years after
diagnosis and 30–78% among those with the highest score
[37, 48].
Regional lymph node involvement Lymph node involve-
ment is a valuable indicator of long-term survival (Fig. 5)
[8, 32]. Node- positive patients have about a 4–8 times
higher mortality than those without nodal involvement
[8, 9, 49]. The more nodes involved the worse the prog-
nosis. Prognosis for patients with 10 or more involved
axillary nodes showed 70% more deaths at 10 years than
for those with 1–3 involved nodes [32]. The survival of
node-positive patients improved due to better staging pro-
cedures and application of systemic treatment [7, 31, 50].
Lymphovascular invasion (LVI) and molecular markers of
tumours angiogenesis At the St. Gallen meeting in 2005,
LVI was added to the prognostics for node-negative pa-
tients [51]. Compared to patients having no LVI, a 60%
higher BC mortality was observed for node-negative BC
patients having positive LVI [52, 53], although others did
not observe the independent role of LVI [46, 50]. In this
line of research, studies have also focused on the value of
microvessel density [44], blood invasion (BVI) [54] and
markers of angiogenesis (VEGFR (vascular endothelial
growth factor receptor), CD105, Tie-2) [55, 56] in pre-
dicting long-term survival of BC patients, although the
results are still conﬂicting.
Fig. 4 Cumulative survival proportion of breast cancer patients
diagnosed in southern Netherlands in 1970–1994 and followed until
2004, according to tumor size (based on pathological diagnosis). n
tumor size: <2 cm (n: 3263) • tumor size: 2–5 cm (n: 3420) m tumor
size: >5 cm (n: 474) x tumor size: involvement of skin (n: 1133) and
unknown/not applicable tumor size: 1410
Fig. 5 Cumulative survival proportion of breast cancer patients
diagnosed in southern Netherlands in 1970–1994 and followed until
2004, according to nodal status (based on pathological diagnosis). n
node negative (n: 4452) • node status: 1–3 positive nodes (n: 3266) m
node status: 4–9 positive nodes (n: 255) x node status: 10+ positive
nodes (n: 189), unknown/not applicable node status: 1538
312 Breast Cancer Res Treat (2008) 107:309–330
123Grouped prognostic factors Some of the prognostic
factors have been combined into a prognostic index, such
as the TNM classiﬁcation and also the more current Not-
tingham Prognostic Index (NPI), both highly predictive for
estimating long-term survival [41]. TNM staging consists
of information on primary tumour size, involvement of the
regional lymph node and the presence of distant metastasis.
Only 53% of patients with regional or locally advanced BC
had survived 10 years after diagnosis compared to 79% of
those with localised BC [16]. Patients with metastasis
(stage: M1) at diagnosis exhibited very poor 10-year
survival (3.4%) [57].
Tumour size, grade and lymph node status make up the
NPI [11, 46, 49]. In a large series of 2879 BC patients,
10-year survival proportion was 85% for those with the
lowest NPI score and 19% for those with the highest score
[11].
Recurrence, metastasis and second cancer
Patients with recurrent, metastasized or second cancer
generally exhibited lower long-term survival than those
without [9, 21, 58–61]. Ten years after surgery, the prob-
ability for survival for another 10 years, thus 20 years after
diagnosis, for node-negative patients aged ‡45 years, tu-
mour £1 cm, grade 1 and without a recurrence or metas-
tasis was 0.89. If a recurrence occurred, the probability of
being alive at 20 years dropped to 0.72. If a metastasis was
observed the probability of survival was only 0.18 [21].
The prognosis decreases with larger primary tumour size,
nodal involvement [62], higher grade,[21] early recurrence
(within 5 years of surgery)[63], location of recurrence
(regional rather than local ipsilateral) [59] and inadequate
primary cancer treatment [9, 64]. In the dataset of the ECR,
overall survival was better for women without second
primary tumours than for women who developed a new
primary cancer (Fig. 6). Only 68% of early BC patients
with second malignancies had survived 10 years of follow-
up compared to 78% of those without multiple cancers
[65]. Younger BC patients are reported to have poorer
survival and a higher risk of second cancer [59]. Corrected
for race and grade, women in the 20-29 year old category
who had a second BC had a probability of 10-year survival
probability of only 23% compared to 57% for those with-
out multiple cancers.
Other tumour markers
Hormone receptors The presence of hormone receptors
such as oestrogen (ER) and progesterone (PR) receptors
predicts the long-term outcome of hormonal therapy [66],
thus they have been more commonly used as a predictive
marker rather than as a prognostic marker. Thus given a
particular treatment, e.g. tamoxifen, ER-positive patients
have a considerably better prognosis than ER-negative
patients. The prognostic value is weak [30, 43] or negli-
gible [37], particularly in the early years after diagnosis
[67].
HER-2 expression Node-positive patients with BC cells
showing ampliﬁcation of the gene for human epidermal
growth factor receptor type 2 (HER2), and/or overexpres-
sion of its product had a lower 10-year overall survival
proportion, 50% versus 65% for those without HER2
ampliﬁcation [17, 68]. After 10 years the difference in
survival persisted, although it became somewhat smal-
ler[17]. Tumours that overexpress HER2 are more likely to
contain p53 abnormalities, to be hormone receptor- and
bcl-2-negative and to have lymphoid inﬁltration and a high
mitotic index, all known to be markers of poor prognosis
for BC [17, 69, 70]. As for patients with node- negative
tumours, HER2 did not seem to affect long-term survival
signiﬁcantly [17, 37, 69]. HER-2 expression has been
valuable in predicting treatment responses to trastuzumab,
certain endocrine therapies and chemotherapy, adding to
it’s role as a predictive marker [68].
Mitotic Activity Index (MAI) MAI is an indicator of tu-
mour proliferative activity that represents the mitotic
activity in a given area of the tumour. Combined with
another prognostic factor (NCHG), MAI has proven to be
an accurate tool for assessment of long-term survival [48].
In a population-based study women with node-negative
tumours <5 cm and a MAI ‡10 exhibited 80% survival at
10 years compared to 90% for an MAI <10 [71].
Gene expression proﬁle A very promising new ﬁnding is
the microarrays method, in which a set of intrinsic genes is
Fig. 6 Cumulative survival of breast cancer patients diagnosed in
southern Netherlands in 1970–1994 and followed-up until 2004,
according to second cancer. Follow-up for patients with second
cancer begins at the date of second cancer diagnosis. n no second
cancer (n: 8137) • second breast cancer (n: 744) m second non-breast
cancer (n: 819)
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123clustered and segregated into major subgroups; BC with a
good and poor prognosis proﬁle is correlated to the prob-
ability of distant metastases [72] or a tumour with basal or
luminal characteristics which are strongly associated with
ER status [73]. In a study of 295 patients diagnosed with
stage I or II breast cancer, those classiﬁed as having a good
prognosis proﬁle had a 95% overall 10-year survival rate
compared to 55% for those with a poor proﬁle [74]. This
classiﬁcation predicted outcome regardless of the nodal
status, implying that more accurate criteria have become
available for administering adjuvant systemic treatment.
Various molecular markers BRCA1 & 2 mutations were
ﬁrst identiﬁed in 1994 and are BC risk factors for some
speciﬁc groups [75]. Their role as prognostic indicator for
long-term (more than 10-year) survival has not yet been
established. A study of 496 women (median follow-up:
116 months), 56 of whom (11%) carried a BRCA1/BRCA2
mutation, showed worse BC-speciﬁc survival for women
with BRCA1 mutations than for those without (62% at
10 years versus 86%; P < 0.0001), but not for women with
the BRCA2 mutation [76]. However, another study which
compared patients from BRCA1, BRCA2 and non-
BRCA1/2 families as well as sporadic cases did not con-
ﬁrm the prognostic role of BRCA1/2 [77].
Long-term follow-up studies have not demonstrated an
independent effect of p53 mutations on long-term survival.
The P53 mutation was related to a poor clinical proﬁle for
patients, hence in multivariate analysis its role on survival
diminished [10, 69, 78, 79].
A high level of tissue urokinase-type plasminogen
activator (uPA) and its inhibitors has been correlated with
poor outcome for node-negative and node-positive patients.
Those having the highest level of uPA have a ﬁve times
greater risk of dying from BC compared to those with the
lowest level [69]. Other factors such as Ki67 (MIB-1),
cathepsin-D, DNA ploidy and S-phase have been suggested
as prognosticators of survival, with conﬂicting results,
particularly among long-term survivors. Their use in gen-
eral clinical settings is therefore not recommended [80, 81].
Miscellaneous
Lifestyle Generally, increased death rates due to BC
(13–20%), other causes (49–86%) and all causes
(14–70%) have been observed among obese patients
[82–85]. Normal body weight tended be more beneﬁcial
in death from other causes than from BC: [83, 84] 9.5%
of obese patients died from non-BC causes compared to
6.4% and 5.8%, respectively, of the normal or interme-
diate groups [82]. Obesity was also related to a 2-fold
increased risk of postmenopausal contralateral BC and a
60% higher occurrence of second other cancers [84].
Therefore, normal weight may reduce the risk of second
post-menopausal BC, second other cancers and overall
mortality [83, 84, 86].
Compared with women who engaged in less than 9
metabolic equivalent task (MET)-hours per week of
activity, women who engaged in 9 or more MET-hours per
week had a 40% lower risk of death from all causes,
translating into a 6% absolute (unadjusted) reduction in
mortality [87], which emphasizes the need to advise
physical activity.
So far, although studies have not convincingly shown
the positive inﬂuence of eating fruit, vegetables and soy
bean on long-term BC survival [85, 88], diets high in fruits,
vegetables, legumes, poultry, and ﬁsh and a low intake of
red meat, desserts and high fat dairy products are likely to
protect against mortality from non-BC causes [89].
Modiﬁcation of BC’s prognostic factors
Various studies have questioned the role of BC risk factors
in determining the biological tumour features as mentioned
above. Indeed, BC risk factors seem to differ according to
histological type, grade, size, nodal status and ER/PR
receptor status [90–93]. For example, excessive alcohol
intake and obesity increased the risk for the development of
ER-positive tumours [92, 93]. As for late age at ﬁrst full-
term birth and obesity are related to an increased risk of
large tumours [91]. Hence, risk factors for BC may also
affect breast biology and clinical behaviour, thus also BC
prognosis.
Changing importance of prognostic factors over time
after diagnosis
Commonly, the value of prognostic factors decreases
depending on the length of the follow-up period [31, 94].
Survival curves according to prognostic factors usually
show a large drop in survival for all stages during the ﬁrst
5 years; afterwards the curve stabilizes. Studies agreed on
the long-lasting inﬂuence of tumour size at diagnosis on
survival, albeit attenuating over time [31, 94, 95]. Grade,
nodal status and metastases were also valuable in predict-
ing survival up to 20 years after diagnosis [31, 95]. Al-
though, others have reported that 10 years after diagnosis
only tumour size [94] or nodal status [8] or old age [8]
remained as an independent predictor of long-term sur-
vival. Similarly, ER/PR status and MAI only had a sig-
niﬁcant prognostic role in the ﬁrst 5–10 years after
diagnosis [67, 71, 96]. Because even 10 years after BC
diagnosis the probability of survival for BC patients does
not seem to reach that of the general population, the role of



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































326 Breast Cancer Res Treat (2008) 107:309–330
123other prognostic factors in determining survival for long-
term survivors still needs to be determined.
The role of early detection
Increased awareness among women and improvement in
diagnostic procedures have enabled earlier and better
detection of BC. Trials on population screening have re-
ported 21–29% reduction in BC mortality for women in-
vited for screening within 14–16 years of follow-up [19,
97]. Screening identiﬁed tumours at an early stage conse-
quently, survival improved [98, 99]. Screening also iden-
tiﬁed patients with slowly growing tumours who might
receive unnecessarily aggressive cancer treatment. Thus,
Joensuu et al. [100] examined recurrence rates among pa-
tients detected by screening compared to those detected
outside screening. After adjusting for tumour aggressive-
ness (tumour size, nodal status, grade, age, treatment, PR
status, HER-2), hence eliminating bias towards detection of
indolent cancers (length bias), the beneﬁt of screening for
the prognosis for BC patients remained evident.[100]T h i s
suggests that other factors explain the indolent behaviour
of BC detected by screening. Hence, until this factor is
established, detection mode should probably be considered
as a prognostic factor and thus be taken into account in
patient management.
The role of treatment
Improvement in BC treatment has undoubtedly also in-
creased the long-term survival of BC patients [101], as
reﬂected by the improved overall survival across all BC
stages [16]. Using historical data from population-based
studies in periods when effective treatment was not avail-
able, it was estimated that without treatment only 4% of
BC patients would survive 10 years or longer [102]. BC
treatment guidelines have been modiﬁed continuously in
the last 28 years, tailored to most of the prognosticators
mentioned earlier [51]. Effectiveness of various treatment
modalities has been summarized by others who conclude
that radiation, chemotherapy and hormonal therapy may
reduce long-term mortality by up to 57% [66, 103–105].
Emerging new therapeutic approaches using a monoclonal
antibody directed against HER-2 have yielded improved
short-term survival for advanced stage [106] as well as
operable BC patients [107]. Quality of treatment as
indicated by loco-regional failure [108], surgeon workload
[109] or hospital volume [110], may affect survival
although its role on long-term survival still needs conﬁr-
mation. In conclusion, on the one hand we have observed a
shift in stage towards less aggressive cancers; on the other
hand, better and more (systemic) treatment has become
available, leading to improved survival for BC patients.
Conclusion
The prognosis of BC has become relatively good, with cur-
rent 10-year relative survival about 70% in most western
populations [16, 111], especially if up-to-date statistical
method such as the period analyses is used [111] (Table 1).
Even better, the longer patients survive their BC the higher
their survival chance [16]. Our review shows conventional
prognostic factors of survival, such as tumour size, lymph
node status and grade, remain the most important determi-
nants of 10-year survival for BC patients (Table 2). Most
studiesagreedonthevalueofMAIandLVIforpredictionof
long-term survival. The inﬂuence of host factors including
age, race/ethnicity or socio-economic factors and tumour-
related factors such as histological type and angiogenesis
diminishes after correctionforotherfactors. For mostrecent
markers such as Her2, gene proﬁling, p53 mutation and uPA
levellongerfollow-upisneeded.Recurrence,metastasesand
a second cancer double the burden of disease thus increase
risk of mortality. Similarly, co-occurrence with other dis-
eases is in no doubt decrease survival.
Healthier lifestyle generally increases long-term sur-
vival. Modiﬁable risk factors (such as alcohol consumption
and obesity) not only affect incidence but also tumour’
clinical behaviour and thus survival.
Although a lot is known about the prognosis for BC
patients, effect of traditional prognostic factors appears to
attenuate over time, leaving room for studies on the role of
other and newer factors for long-term survival.
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